- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06047964
Paclitaxel Drug-eluting Balloon Catheters in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis and Restenosis
A Prospective, Multicenter, Clinical Trial to Evaluate the Safety and Effectiveness of the Intracranial Paclitaxel Drug-eluting Balloon Catheters (SeQuent® Please CIS) in the Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis and Restenosis After Interventional Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study includes 2 sub-studies, sub-study A and sub-study B, namely.
Sub-study A is a prospective, multicenter, randomized controlled, superior clinical trial to evaluate the safety and effectiveness of paclitaxel drug-releasing intracranial balloon catheter (SeQuent® Please CIS) in the treatment of symptomatic intracranial atherosclerotic stenosis.
Sub-study B is a prospective, multicenter, single-arm clinical trial designed to evaluate the safety and efficacy of paclitaxel drug-releasing intracranial balloon catheter (SeQuent® Please CIS) for the treatment of restenosis following interventional treatment for symptomatic intracranial atherosclerotic stenosis.
A total of 277 subjects are expected to be enrolled, including 252 subjects in sub-study A and 25 subjects in sub-study B. Subjects enrolled in sub-study A will be randomized into the study arm and the control arm with the ratio of 1:1. The study arm will be treated with SeQuent® Please CIS (paclitaxel drug-releasing intracranial balloon catheter), while the control arm will be treated with intracranial PTA balloon catheter. Subjects enrolled in sub-study A will all be treated with SeQuent®, Please CIS.
All subjects will be followed up till 12 month post procedure.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Iris Zhang
- Phone Number: +86 10 5763 2775
- Email: Iris.zhang@bbraun.com
Study Contact Backup
- Name: Jason Yan
- Phone Number: +86 21 22163026
- Email: jason.yan@bbraun.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Yan Ma, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 to 80 years old (including boundary value), gender is not limited;
- The target lesion of the patient is a symptomatic intracranial atherosclerotic stenosis lesion (for part A only) or restenosis lesions after interventional therapy (for part B only);
- Symptomatic intracranial arterial stenosis (intracranial segment of internal carotid artery (Petrous segment and above), middle cerebral artery, intracranial segment of vertebral artery, basilar artery, etc.) within 6 months, the degree of stenosis of the diseased artery is between 70% and 99% (WASID method);
- Patients with symptoms occurring more than once (symptoms refer to stroke or transient ischemic attacks) after intensive drug therapy of internal medicine (including antiplatelet therapy, antihypertensive therapy, hypoglycemic therapy and lipid-lowering therapy);
- The intracranial arterial stenosis lesion to be treated is a single lesion;
- Patients with at least 1 risk factor for intracranial atherosclerotic plaque, including previous or existing hypertension, hyperlipidemia, diabetes, smoking;
- Preoperative mRS ≤ 2, and NIHSS≤8;
- Patients whose life expectancy is greater than 12 months as assessed by the investigator.
- Patients or their guardians can understand the trial purpose, voluntarily participate in and sign the informed consent form, and can accept follow-up visits.
Exclusion Criteria:
- Severe calcification in the target vessel, severe distortion of the target vessel or anatomical factors that make it hard for interventional devices to be in place;
- Ischemic symptoms are only associated with branch events;
- Severe stenosis or occlusion of tandem extracranial or intracranial vessels at the proximal or distal end of the target vessel;
- Angioplasty or stenting procedures is planned for extracranial vascular lesions with tandem intracranial vessels;
- History of endarterectomy in the extracranial segment of carotid artery and vertebral artery within 30 days;
- The target vessel has previously been treated with stenting or angioplasty or other mechanical devices (for Part A only);
- Acute or subacute intraluminal thrombosis is found in the target vessel;
- Patients with intracranial stenosis combined with aneurysm, intracranial tumor or intracranial vascular malformation, or intracranial arterial spasm without significant stenosis;
- Intracranial hemorrhage (cerebral intraparenchymal hemorrhage, massive subarachnoid hemorrhage, and subdural/epidural hemorrhage) within 3 months;
- There are cardiogenic stroke or risk factors that may contribute to cardioembolism, such as fibrillation, left ventricular thrombosis or myocardial infarction within 6 weeks,;
- Patients with abnormal coagulation function or bleeding tendency (e.g., international normalized ratio (INR) > 1.5);
- Patients with known hypersensitivity to iodine contrast medium, paclitaxel, or iopromide;
- Patients who are participating in clinical trials of other drugs or devices;
- Other conditions that the investigator deems the patient unsuitable for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: De-novo DCB group
Patients with de-novo symptomatic intracranial atherosclerotic stenosis and treated with DCB
|
Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
|
Active Comparator: De-novo POBA group
Patients with de-novo symptomatic intracranial atherosclerotic stenosis and treated with POBA
|
Intracranial PTA balloon catheter
|
Experimental: Restenosis group
Patients with symptomatic intracranial atherosclerotic re-stenosis after interventional therapy and treated with DCB
|
Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
restenosis incidence of target lesion
Time Frame: 6 months post-procedure
|
angiographic restenosis measured by WASID ( Warfarin-Aspirin Symptomatic Intracranial Disease) method in core-lab
|
6 months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device success rate
Time Frame: baseline procedure
|
Successful delivery, dilatation and withdraw of the balloon
|
baseline procedure
|
The changes of Modified Rankin Scale(mRS) score
Time Frame: 6 and 12 months post-procedure
|
Scores range from 0 to 6, with higher scores indicating more severe nerve damage; Change of mRS score = mRS score at 6 months (12 months) after surgery - mRS score at baseline
|
6 and 12 months post-procedure
|
The changes of NIH Stroke Scale(NIHSS) score
Time Frame: 6 and 12 months post-procedure
|
Scores range from 0 to 42, with higher scores indicating more severe nerve damage; Change of NIHSS score = NIHSS score at 6 months (12 months) after surgery - NIHSS score at baseline.
|
6 and 12 months post-procedure
|
Number and incidence (%) of target vessel stroke events (including ischemic or hemorrhagic stroke), transient ischemic attack
Time Frame: 6 and 12 months post-procedure
|
Incidence of target vessel stroke events (%) = (number of subjects with target vessel stroke events/total number of subjects) × 100%. Incidence of transient ischemic attacks (%) = (number of subjects with transient ischemic attacks/total number of subjects) × 100%. |
6 and 12 months post-procedure
|
Recurrence incidence of ipsilateral ischemic stroke
Time Frame: 30 days, 6 and 12 months post-procedure
|
Recurrence incidence of ipsilateral ischemic stroke (%) = (number of subjects with recurrent ipsilateral ischemic stroke/total number of subjects) × 100%.
|
30 days, 6 and 12 months post-procedure
|
Collaborators and Investigators
Investigators
- Principal Investigator: Liqun Jiao, MD, Xuanwu Hospital, Beijing
- Principal Investigator: Yan Ma, MD, Xuanwu Hospital, Beijing
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPINAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on DCB
-
Yonsei UniversityRecruitingFemoropopliteal Artery DiseaseKorea, Republic of
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecruiting
-
Acotec Scientific Co., LtdShanghai Tongji Hospital, Tongji University School of MedicineRecruiting
-
C. R. BardCompletedFemoral Artery Occlusion | Femoral Artery Stenosis | Stenosis of Popliteal Arteries | Occlusion of Popliteal ArteriesChina
-
Acotec Scientific Co., LtdRecruitingStenosis of Native Hemodialysis Arteriovenous FistulasChina
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Norfolk and Norwich University Hospitals NHS Foundation...University of East AngliaRecruiting
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingCoronary Artery DiseaseChina
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Istituto Clinico Sant'AmbrogioUnknownCoronary Artery DiseaseItaly